{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05763563",
            "orgStudyIdInfo": {
                "id": "MCC-22115"
            },
            "organization": {
                "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy",
            "officialTitle": "Feasibility Of Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "exercise-prehabilitation-among-older-patients-with-hematological-malignancies-preparing-for-car-t-cell-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-28",
            "studyFirstSubmitQcDate": "2023-02-28",
            "studyFirstPostDateStruct": {
                "date": "2023-03-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Cancer and Aging Research Group",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to evaluate an exercise program for individuals preparing for Chimeric Antigen Receptor (CAR) T-cell immunotherapy for hematological malignancies."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoma",
                "Leukemia",
                "Myeloma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Exercise prehabilitation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo CAR-T therapy (Approximately 4-6 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.",
                    "interventionNames": [
                        "Behavioral: Resistance Training",
                        "Behavioral: Aerobic Exercise"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Resistance Training",
                    "description": "Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.",
                    "armGroupLabels": [
                        "Exercise prehabilitation"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Aerobic Exercise",
                    "description": "Participants will be encouraged to perform \u226530 minutes of moderate-intensity aerobic exercise on \u22653 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation",
                    "armGroupLabels": [
                        "Exercise prehabilitation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants that Enroll and Consent - Enrollment Feasibility",
                    "description": "Enrollment will be considered feasible if \u226560% of eligible and approached patients actually consent and enroll",
                    "timeFrame": "Up to 12 Months"
                },
                {
                    "measure": "Percentage of Participants that Complete Study Assessments - Retention Feasibility",
                    "description": "Retention will be considered feasible if \u226570% of participants complete study measures",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Adherence - Feasibility",
                    "description": "Adherence will be based on participants attending \u2265 70% of tele-RT sessions on average and performing \u2265 70% of prescribed moderate-intensity aerobic exercise per week",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Participant Evaluation of Feasibility and Acceptability - Acceptability",
                    "description": "Participants evaluation of feasibility and acceptability will be assessed with a questionnaire, adapted to fit the intervention. The questionnaire includes both Likert Scale and open-ended questions. An item-by-item basis and as average item score, with scores \u22654 (\"agree\" to \"strongly agree\") indicating acceptability. Open-ended responses will be analyzed qualitatively to inform intervention improvement.",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Participant Self-Reported Musculoskeletal Injuries - Safety",
                    "description": "The numerator of the safety variable will be the number of musculoskeletal injuries or adverse health events reported as \"likely related\" or \"definitely related\" the exercise programming and that caused at least some limitation of daily activity lasting more than 3 days. The denominator of the safety variable will be the number of exercise sessions performed by the participant (tele-resistance training plus aerobic exercise sessions lasting \u226510 minutes). The intervention will be considered safe if the rate of musculoskeletal injuries (i.e., muscle strains or pulls, sprains, exacerbated bone pain, fractures or breaks, or other adverse health events incurred during exercise sessions) is lower than the published metric of 11.9 injuries per 1000 sessions, as used as a benchmark in previous exercise oncology research",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Objective physical functioning and fitness - Baseline",
                    "description": "Physical functioning and fitness will be assessed using the 30-second chair stand test,30-second arm curl test, and treadmill 6-minute walk test.",
                    "timeFrame": "At Baseline"
                },
                {
                    "measure": "Objective physical functioning and fitness - Follow-up",
                    "description": "Physical functioning and fitness will be assessed using the 30-second chair stand test,30-second arm curl test, and treadmill 6-minute walk test.",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Participant Skeletal Muscle Index (SMI) - Baseline",
                    "description": "Participants SMI will be measured using Tomovision SliceOMatic software and clinical, computerized tomography (CT) scans",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Participant Skeletal Muscle Index (SMI) - Follow-up",
                    "description": "Participants SMI will be measured using Tomovision SliceOMatic software and clinical, computerized tomography (CT) scans",
                    "timeFrame": "After CAR-T Therapy, Up to 6 Months"
                },
                {
                    "measure": "Participants Health-Related Quality of Life - Baseline",
                    "description": "Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Participants Health-Related Quality of Life - At 3 Months",
                    "description": "Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Participants Health-Related Quality of Life - At 6 Months",
                    "description": "Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey",
                    "timeFrame": "Up to 6 Months"
                },
                {
                    "measure": "Participant Self Reported Exercise - Baseline",
                    "description": "Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Participant Self Reported Exercise - At 3 Months",
                    "description": "Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise",
                    "timeFrame": "Up to 3 Months"
                },
                {
                    "measure": "Participant Self Reported Exercise - At 6 Months",
                    "description": "Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise",
                    "timeFrame": "Up to 6 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226565 years\n* Lymphoma, leukemia, or myeloma with commercial FDA-approved CAR-T delivery planned for \u22654 weeks following enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Able to read and speak English fluently\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Regular engagement in Resistance training (2x/week targeting all major muscle groups)\n* Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions\n* Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).\n* Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT using body weight\n* Numeric pain rating scale of \u2265 7 out of 10\n* Myopathic or rheumatologic disease that impacts physical function\n* Cognitive, visual, or auditory limitations that preclude safe engagement in remotely-supervised resistance training sessions or independent aerobic exercise (as determined by patients' treating oncologists and specified in clinic notes outlining disease history).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "65 Years",
            "stdAges": [
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nathan Parker, PhD, MPH",
                    "role": "CONTACT",
                    "phone": "813-745-4673",
                    "email": "Nathan.Parker@moffitt.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nathan Parker, PhD, MPH",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Ciara Freeman, MD, PhD",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rachel Carmella",
                            "role": "CONTACT",
                            "phone": "813-745-0956",
                            "email": "rachel.carmella@moffitt.org"
                        },
                        {
                            "name": "Nathan Parker, PhD, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ciara Freeman, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Frederick Locke, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Michael Jain, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Julio Chavez, MD, MS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Bijal Shah, MD, MS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Omar Casteneda Pugliani, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Doris Hansen, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Taiga Nishihori, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Melissa Alsina, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Brandon Blue, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Rachid Baz, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Rawan Faramand, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Heather Jim, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Laura Oswald, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jongphil Kim, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Moffitt Cancer Center Clinical Trial Search",
                    "url": "https://moffitt.org/clinicaltrialssearch?DiseaseSite=&q=22115"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematological Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}